The U.S. FDA has implemented a "green list" import alert to prevent unsafe GLP-1 APIs from unverified foreign sources from entering the U.S. market. FDA-approved GLP-1 drugs like Novo Nordisk A/S' semaglutide and Eli Lilly and Co.'s tirzepatide are used for type 2 diabetes and weight management. Patients are opting for compounded versions not approved by the FDA. The green list will feature GLP-1 APIs from compliant facilities inspected by the FDA to safeguard patients. For more details, visit Benzinga.com.